Astrazeneca

FromAstraZeneca ([email protected])
Subject (45)Dato-DXd new BLA submitted, NSQ BLA withdrawn
Preheader (149)Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell
Typography
Arial
Colors
Text Analysis
Body Words236
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px798 px
X-Spam Score0.9
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeMorning

Dato-DXd new BLA submitted, NSQ BLA withdrawn

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell
Dato-DXd new BLA submitted, NSQ BLA withdrawn